Labcorp adds new COVID-19 antigen test to repertoire

By staff writers

February 18, 2021 -- Labcorp has added a new high sensitivity antigen test for screening for active COVID-19 disease to its testing offerings. The nasal swab test was developed by DiaSorin.

The test is called Liaison SARS-CoV-2, and it was cleared by the U.S. Food and Drug Administration (FDA) in October of 2020. The test is available through a doctor's order, Labcorp said. Results are available within 24 to 48 hours.

CDC awards Labcorp SARS-CoV-2 sequencing contract
The U.S. Centers for Disease Control and Prevention (CDC) has awarded Labcorp a contract to provide genomic sequencing of samples of the SARS-CoV-2 virus.
Labcorp gets EUA for Pixel at-home COVID-19 kits
Labcorp has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for Pixel by Labcorp, a kit that will enable users...
Labcorp revenue, earnings surge in Q3
Revenue gains from COVID-19 testing helped propel Labcorp to a 33% increase in revenue in its third quarter. The company said that revenue climbed due...
Labcorp debuts combined COVID-19, flu, and RSV test
Labcorp has launched a combined test for COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The single-panel test is now available throughout...
FDA clears DiaSorin's Simplexa varicella-zoster virus test
DiaSorin Molecular's Simplexa DNA swab test for the varicella-zoster virus is now cleared by the U.S. Food and Drug Administration (FDA).

Copyright © 2021

Last Updated ls 2/18/2021 1:40:14 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current